●SK chemicals receives the Osong New Drug Award.In recognition of its development of the world’s first quadrivalent cell culture-based influenza vaccine ‘Sky Cell Flu Quadrivalent.’
- SK chemicals receives the Osong New Drug Award at K-Health Leaders Forum 2016.
- Its contributions to the bio industry, and specifically development of the quadrivalent cell culture-based influenza vaccine, were recognized.
SK chemicals received the New Drug Award.
SK chemicals announced on September 2 that it received the ‘Osong New Drug Award,’ the Minister of Food and Drug Safety’s award, at K-Health Leaders Forum 2016, hosted by the Ministry of Food and Drug Safety and the Korea Economic Daily TV and sponsored by Korea Biotechnology Industry Organization.
At the awards ceremony, which celebrates its 7th anniversary this year, SK chemicals received this award in recognition of its contributions in the field of influenza vaccines. A Forum insider said, “SK chemicals has taken the lead in localizing vaccines and has contributed to reinforcing the competitiveness of the domestic bio industry, e.g., the world’s first successfully commercialized quadrivalent cell culture-based influenza vaccine.”
SK chemicals launched ‘Sky Cell Flu Quadrivalent, the world’s first quadrivalent cell culture-based influenza vaccine on August 23, and created a sensation in the vaccine market.
Sky Cell Flu Quadrivalent is capable of vaccination against four kinds of influenza viruses with a single injection, and unlike the existing egg-based production of vaccines, it introduced the cell culture-based technology using a sterile incubator, and eliminated the use of antibiotics from the production process. Also, it is the only domestic quadrivalent influenza vaccine that can be used to vaccinate all children three years of age and older.
“SK Chemical’s investments in vaccines during the past decade are beginning to steadily show results,” said Han Byeong-ro, CEO of SK chemicals, who received the award. “We will work harder to make sure that our products become the most successful vaccines all over the word as well as in Korea.”
SK chemicals released the first vaccine product, ‘Sky Cell Flu,’ a trivalent cell culture-based influenza vaccine, last year, and is now developing premium vaccines, such as herpes zoster and streptococcus pneumoniae vaccines.
K-Health Leaders Forum has shared the performance of domestic companies in R&D, exports and the bio industry, and selected and given awards to the highest contributors to the development of the industry since 2010. At the awards ceremony, LG Life Sciences, Boryung Pharmaceutical Company, Green Cross Corp., etc. received awards.
[Photo]
"Han Byeong-ro, CEO of SK chemicals, receives the Osong New Drug Award at ‘K-Health Leaders Forum 2016’ from Yoo Moo-yeong, Ministry of Food and Drug Safety.